Trial Profile

A Phase II Trial of 177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
Indications Neuroblastoma
Focus Therapeutic Use
Acronyms LuDO-N

Most Recent Events

16 Sep 2023 Planned number of patients changed from 24 to 25.
31 May 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT04903899).
25 May 2021 Planned End Date changed from 3 Feb 2031 to 20 May 2031.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com